Denali Therapeutics (NASDAQ:DNLI) Issues Earnings Results

Denali Therapeutics (NASDAQ:DNLI) released its quarterly earnings data on Thursday. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.17), FiscalAI reports. The firm had revenue of $3.60 million for the quarter, compared to analysts’ expectations of $2.15 million. During the same quarter in the prior year, the firm posted ($0.72) EPS.

Here are the key takeaways from Denali Therapeutics’ conference call:

• AVLAYAH generated $3.6 million in net product revenue during its first full commercial quarter, with commercial payer coverage exceeding 50% of covered lives. Denali expects Q3 revenue of $10 million–$12 million as access expands and more patients transition to treatment.
• Early launch indicators were stronger than anticipated, including high physician and family engagement and demand extending beyond the initially expected group of highly engaged families. Denali estimates roughly 375 U.S. pediatric patients are currently eligible, with additional opportunity from newly diagnosed children.
• Denali strengthened its balance sheet with $195 million from the sale of its Priority Review Voucher, bringing pro forma cash, cash equivalents, and marketable securities to more than $1.1 billion. Management said the capital supports AVLAYAH commercialization, pipeline development, manufacturing investments, and potential strategic flexibility.
• Two blood-brain-barrier Transport Vehicle programs for Alzheimer’s disease advanced into clinical development: DNL628, a tau antisense oligonucleotide, and DNL921, an anti-amyloid antibody. Initial biomarker and safety or proof-of-concept data are expected in 2027.
• Denali pushed DNL593 data to the first half of 2027, from an earlier expectation of year-end 2026, to obtain longer-term follow-up—particularly for neurofilament light-chain and other biomarkers—and assess a potential accelerated-approval strategy.

Denali Therapeutics Price Performance

Shares of Denali Therapeutics stock traded up $0.10 during trading hours on Friday, reaching $24.83. The company’s stock had a trading volume of 1,749,187 shares, compared to its average volume of 1,757,824. The firm has a 50 day moving average price of $23.54 and a 200-day moving average price of $21.28. Denali Therapeutics has a one year low of $12.58 and a one year high of $27.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.28 and a quick ratio of 9.28. The stock has a market cap of $3.94 billion, a P/E ratio of -8.74 and a beta of 1.01.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Leerink Partners cut their price objective on Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, April 22nd. JPMorgan Chase & Co. started coverage on Denali Therapeutics in a research report on Monday, July 13th. They issued an “overweight” rating and a $29.00 target price on the stock. Deutsche Bank Aktiengesellschaft increased their price target on Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Wall Street Zen raised Denali Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Wedbush reaffirmed an “outperform” rating and set a $26.00 price objective on shares of Denali Therapeutics in a report on Monday, July 13th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Denali Therapeutics has an average rating of “Moderate Buy” and an average price target of $35.92.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Denali Therapeutics by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company’s stock valued at $1,210,000 after purchasing an additional 3,432 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Denali Therapeutics by 58.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company’s stock worth $22,732,000 after purchasing an additional 614,555 shares during the period. Empowered Funds LLC boosted its holdings in shares of Denali Therapeutics by 11.0% in the 1st quarter. Empowered Funds LLC now owns 20,639 shares of the company’s stock worth $281,000 after purchasing an additional 2,052 shares during the period. Woodline Partners LP increased its position in shares of Denali Therapeutics by 13.5% during the 1st quarter. Woodline Partners LP now owns 113,517 shares of the company’s stock valued at $1,543,000 after purchasing an additional 13,517 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Denali Therapeutics by 1.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 191,613 shares of the company’s stock valued at $2,681,000 after purchasing an additional 3,210 shares during the last quarter. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.